Medical device company Merit Medical Systems (NASDAQ: MMSI) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 9.5% year on year to $418.8 million. The company’s full-year revenue guidance of $1.64 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.19 per share was 24% above analysts’ consensus estimates.
Is now the time to buy MMSI? Find out in our full research report (it’s free for active Edge members).
Merit Medical Systems (MMSI) Q2 CY2026 Highlights:
- Revenue: $418.8 million vs analyst estimates of $405.3 million (9.5% year-on-year growth, 3.3% beat)
- Adjusted EPS: $1.19 vs analyst estimates of $0.96 (24% beat)
- The company slightly lifted its revenue guidance for the full year to $1.64 billion at the midpoint from $1.62 billion
- Management raised its full-year Adjusted EPS guidance to $4.30 at the midpoint, a 5.4% increase
- Operating Margin: 14.4%, up from 12.3% in the same quarter last year
- Organic Revenue rose 9% year on year (beat)
- Market Capitalization: $5.08 billion
StockStory’s Take
Merit Medical Systems delivered a second quarter that exceeded Wall Street’s expectations, with broad-based growth across both its Foundational and Therapeutic product categories. Management attributed the strong performance to the outperformance of recent acquisitions, notably Biolife and the C2 CryoBalloon, as well as robust organic growth in core platforms like Vascular Intervention and Cardiac Therapies. CEO Martha Aronson highlighted that the company achieved its strongest quarterly organic growth in three years, supported by a rebound in the OEM business and operational improvements that helped expand non-GAAP operating margins. The company also benefited from tariff refunds, but even excluding these, underlying profitability exceeded projections.
Looking forward, Merit Medical Systems’ lifted full-year guidance is underpinned by continued integration of recent acquisitions, targeted expansion in oncology and endoscopy, and a disciplined approach to cost management. Management expects ongoing momentum in its core platforms as well as incremental contributions from new product launches like SCOUT MD and the OneMark system. CFO Raul Parra noted that the outlook factors in tariff uncertainties and typical seasonality, with the company maintaining confidence in its ability to achieve its multi-year growth and profitability targets. Aronson added, “Our organization is aligned around our priorities for 2026, specifically to drive strong execution around the globe and to successfully complete our CGI program.”
Key Insights from Management’s Remarks
Management pointed to the successful integration of acquired businesses, product launches in oncology and endoscopy, and operational improvements as key contributors to the quarter’s strong results.
- Acquisition integration progress: The integration of Biolife and the C2 CryoBalloon device exceeded expectations, contributing to both revenue and margin gains. Biolife’s StatSeal product, targeting hemostasis in various clinical settings, was cited as outperforming initial forecasts.
- Oncology platform expansion: The commercial launch of the OneMark system and SCOUT MD technology broadened the company’s offering in breast and soft tissue tumor localization. Management emphasized that this positions Merit Medical to serve a larger share of the estimated 1.3 million annual procedures in the U.S. market.
- OEM business rebound: The OEM segment, which produces devices for other manufacturers, recovered with 15% year-over-year growth after previous volatility. Management expects this business to grow in the mid to high single digits annually but acknowledged its inherently lumpy nature.
- Operational efficiency gains: Gross margin improvements were attributed to pricing discipline, product mix optimization, manufacturing footprint changes (such as moving operations to Tijuana), and increased automation. These efforts helped offset headwinds like tariffs and supply chain challenges.
- Strategic planning underway: The company continued work on its next three-year strategic plan, focusing on portfolio rationalization, capital allocation, and identifying high-growth opportunities, while maintaining its commitment to completing the current CGI (Continued Growth Initiatives) program.
Drivers of Future Performance
Merit Medical’s updated outlook is driven by sustained momentum in core platforms, product innovation, and ongoing cost discipline, but management notes that tariffs and seasonality may affect short-term trends.
- Product launches and portfolio breadth: Management believes that the continued rollout of new products, such as the SCOUT MD and OneMark systems in oncology, alongside recent expansions in endoscopy, will drive high-single-digit organic revenue growth and enhance market penetration across core therapeutic areas.
- Operational leverage and cost management: The company anticipates further margin improvement by maintaining discipline in operating expenses and leveraging automation and supply chain efficiencies. Parra highlighted that recent manufacturing changes and inventory strategies are expected to support profitability even as tariffs remain a risk factor.
- Tariff and macroeconomic uncertainty: While the company remains confident in its guidance, management cautioned that unpredictable changes to tariff regulations and global economic conditions could introduce volatility in future quarters, prompting a wider-than-usual range in near-term margin and earnings guidance.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will be watching (1) the pace of adoption and revenue contribution from new oncology and endoscopy products, (2) the ability of the OEM segment to sustain improved growth on an annualized basis despite inherent volatility, and (3) progress on cost containment and operational efficiency as tariffs and supply chain disruptions persist. Additionally, updates on the company’s next three-year strategic plan and further M&A activity will be critical indicators of long-term growth potential.
Merit Medical Systems currently trades at $84.21, up from $83.35 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
